WO1994010204A1 - Protein fragments of the pectinatus bacterium - Google Patents
Protein fragments of the pectinatus bacterium Download PDFInfo
- Publication number
- WO1994010204A1 WO1994010204A1 PCT/FI1993/000431 FI9300431W WO9410204A1 WO 1994010204 A1 WO1994010204 A1 WO 1994010204A1 FI 9300431 W FI9300431 W FI 9300431W WO 9410204 A1 WO9410204 A1 WO 9410204A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ala
- asn
- val
- ser
- asp
- Prior art date
Links
- 241000606012 Pectinatus Species 0.000 title claims abstract description 31
- 102000004169 proteins and genes Human genes 0.000 title description 41
- 108090000623 proteins and genes Proteins 0.000 title description 41
- 239000012634 fragment Substances 0.000 title description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 49
- 239000000427 antigen Substances 0.000 claims abstract description 14
- 108091007433 antigens Proteins 0.000 claims abstract description 14
- 102000036639 antigens Human genes 0.000 claims abstract description 14
- 230000000890 antigenic effect Effects 0.000 claims abstract description 12
- DXZNJWFECGJCQR-FXQIFTODSA-N Asn-Asn-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N DXZNJWFECGJCQR-FXQIFTODSA-N 0.000 claims abstract description 11
- JBDLMLZNDRLDIX-HJGDQZAQSA-N Asn-Thr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O JBDLMLZNDRLDIX-HJGDQZAQSA-N 0.000 claims abstract description 11
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 claims abstract description 11
- AOILQMZPNLUXCM-AVGNSLFASA-N Val-Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN AOILQMZPNLUXCM-AVGNSLFASA-N 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 9
- AAQGRPOPTAUUBM-ZLUOBGJFSA-N Ala-Ala-Asn Chemical group [H]N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O AAQGRPOPTAUUBM-ZLUOBGJFSA-N 0.000 claims abstract description 8
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 claims abstract description 8
- BRRPVTUFESPTCP-ACZMJKKPSA-N Asp-Ser-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O BRRPVTUFESPTCP-ACZMJKKPSA-N 0.000 claims abstract description 8
- QPDUWAUSSWGJSB-NGZCFLSTSA-N Asp-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N QPDUWAUSSWGJSB-NGZCFLSTSA-N 0.000 claims abstract description 8
- GFHXZNVJIKMAGO-IHRRRGAJSA-N Pro-Phe-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O GFHXZNVJIKMAGO-IHRRRGAJSA-N 0.000 claims abstract description 8
- PZZJMBYSYAKYPK-UWJYBYFXSA-N Ser-Ala-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O PZZJMBYSYAKYPK-UWJYBYFXSA-N 0.000 claims abstract description 8
- 108010077245 asparaginyl-proline Proteins 0.000 claims abstract description 8
- 241000880493 Leptailurus serval Species 0.000 claims abstract description 5
- 108010048397 seryl-lysyl-leucine Proteins 0.000 claims abstract description 5
- YHOPXCAOTRUGLV-XAMCCFCMSA-N Ala-Ala-Asp-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O YHOPXCAOTRUGLV-XAMCCFCMSA-N 0.000 claims abstract description 4
- RGKKALNPOYURGE-ZKWXMUAHSA-N Asp-Ala-Val Chemical compound N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O RGKKALNPOYURGE-ZKWXMUAHSA-N 0.000 claims abstract description 4
- XUDRHBPSPAPDJP-SRVKXCTJSA-N Ser-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO XUDRHBPSPAPDJP-SRVKXCTJSA-N 0.000 claims abstract description 4
- 150000001413 amino acids Chemical group 0.000 claims description 28
- HYSVGEAWTGPMOA-IHRRRGAJSA-N Lys-Pro-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O HYSVGEAWTGPMOA-IHRRRGAJSA-N 0.000 claims description 7
- 108010050848 glycylleucine Proteins 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 5
- APHUDFFMXFYRKP-CIUDSAMLSA-N Asn-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N APHUDFFMXFYRKP-CIUDSAMLSA-N 0.000 claims description 4
- PNHQRQTVBRDIEF-CIUDSAMLSA-N Asn-Leu-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)N PNHQRQTVBRDIEF-CIUDSAMLSA-N 0.000 claims description 4
- 241000604449 Megasphaera Species 0.000 claims description 4
- DSZFTPCSFVWMKP-DCAQKATOSA-N Met-Ser-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN DSZFTPCSFVWMKP-DCAQKATOSA-N 0.000 claims description 4
- XCVRVWZTXPCYJT-BIIVOSGPSA-N Ala-Asn-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N XCVRVWZTXPCYJT-BIIVOSGPSA-N 0.000 claims description 3
- XAXMJQUMRJAFCH-CQDKDKBSSA-N Ala-Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 XAXMJQUMRJAFCH-CQDKDKBSSA-N 0.000 claims description 3
- MGSVBZIBCCKGCY-ZLUOBGJFSA-N Asp-Ser-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MGSVBZIBCCKGCY-ZLUOBGJFSA-N 0.000 claims description 3
- JSGWNFKWZNPDAV-YDHLFZDLSA-N Phe-Val-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 JSGWNFKWZNPDAV-YDHLFZDLSA-N 0.000 claims description 3
- XBJKAZATRJBDCU-GUBZILKMSA-N Val-Pro-Ala Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O XBJKAZATRJBDCU-GUBZILKMSA-N 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 3
- 238000002649 immunization Methods 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 3
- 230000001268 conjugating effect Effects 0.000 claims description 2
- LVHMEJJWEXBMKK-GMOBBJLQSA-N Asn-Ile-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC(=O)N)N LVHMEJJWEXBMKK-GMOBBJLQSA-N 0.000 abstract 1
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 abstract 1
- GLYJPWIRLBAIJH-UHFFFAOYSA-N Ile-Lys-Pro Natural products CCC(C)C(N)C(=O)NC(CCCCN)C(=O)N1CCCC1C(O)=O GLYJPWIRLBAIJH-UHFFFAOYSA-N 0.000 abstract 1
- RRIHXWPHQSXHAQ-XUXIUFHCSA-N Met-Ile-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(O)=O RRIHXWPHQSXHAQ-XUXIUFHCSA-N 0.000 abstract 1
- FXGIMYRVJJEIIM-UWVGGRQHSA-N Pro-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FXGIMYRVJJEIIM-UWVGGRQHSA-N 0.000 abstract 1
- HDBOEVPDIDDEPC-CIUDSAMLSA-N Ser-Lys-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O HDBOEVPDIDDEPC-CIUDSAMLSA-N 0.000 abstract 1
- WNZSAUMKZQXHNC-UKJIMTQDSA-N Val-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N WNZSAUMKZQXHNC-UKJIMTQDSA-N 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 39
- 235000001014 amino acid Nutrition 0.000 description 24
- 229940024606 amino acid Drugs 0.000 description 24
- 102000004196 processed proteins & peptides Human genes 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 10
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 8
- 241000008319 Pectinatus cerevisiiphilus Species 0.000 description 8
- 101800005149 Peptide B Proteins 0.000 description 7
- 101710154545 16 kDa protein Proteins 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 239000002344 surface layer Substances 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 4
- 210000004898 n-terminal fragment Anatomy 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000013405 beer Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229960000443 hydrochloric acid Drugs 0.000 description 3
- 235000011167 hydrochloric acid Nutrition 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 108010091748 peptide A Proteins 0.000 description 3
- 108010005636 polypeptide C Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 1
- REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 description 1
- QXHVOUSPVAWEMX-ZLUOBGJFSA-N Asp-Asp-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXHVOUSPVAWEMX-ZLUOBGJFSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102100021277 Beta-secretase 2 Human genes 0.000 description 1
- 101710150190 Beta-secretase 2 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- MYZMQWHPDAYKIE-SRVKXCTJSA-N Lys-Leu-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O MYZMQWHPDAYKIE-SRVKXCTJSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001529548 Megasphaera cerevisiae Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100021941 Sorcin Human genes 0.000 description 1
- 101710089292 Sorcin Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical class [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the invention relates to protein fragments i.e. peptides of the Pectinatus bacteria useful in the detection and identification of the Pectinatus bac ⁇ teria.
- the invention also relates to antibodies raised against the peptides, to a method for detecting the Pectinatus bacteria by means of the antibodies, and to the use of the peptides according to the invention as antigens.
- Pectinatus is a Gram-negative, rod-shaped, anaerobic bacterium described for the first time in 1978 (Lee S.Y. et al . , 1978, Int . J. Syst . Bacteriol . , 28, 582-594).
- the bacterium was isolated from turbid beer, and has thereafter been found in breweries in different parts of the world. It is a dreaded, highly harmful contaminant in breweries.
- a characteristic feature of Pectinatus is that it has flagellae located on one side of the cell only.
- the Pectinatus bacteria produce organic acids, such as propionic acid and sulphur compounds which spoil the flavour of beer.
- the protein patterns of the Pectinatus bacteria have been studied.
- the bacterial cells have been extracted by a mild hydrochloric acid solution which removes the surface layer of the cell, and the extracts have then been subjected to SDS polyacryl- amide gel electrophoresis (SDS-PAGE).
- SDS-PAGE SDS polyacryl- amide gel electrophoresis
- the Pectinatus bacteria have been divided into two main groups on the basis of the presence or absence of the 22 kDa protein. These groups have further been divided into at least five subgroups on the basis of other major proteins.
- Pectinatus There are also proteins common to all groups, such as the proteins having an apparent molecular weight of about 48 to 53 kDa and about 16 kDa (Hakalehto E. et al . , 1984, Food Microbiology , 1 , 209-216).
- the main groups of Pectinatus have more recently been divided into two species, viz. Pectinatus fri- singiensis and Pectinatus cerevisiiphilus (Schleifer K. H. et al . , 1990, Int . J. Syst. Bacteriol . 40, 19- 27).
- the antigenic properties of the components of the surface layer of the Pectinatus bacteria have also been studied.
- the Pectinatus bacteria can be divided into two main groups even on the basis of these results: the size of the main antigenic component of one group is about 55 to 78 kDa, depending on the strain, and that of the other group about 22 to 25 kDa (Hakalehto E. and Finne J., 1990, FEMS Microbiology Letters 67, 307-312).
- the N- terminal fragments of the above-described proteins having the size of about 48 to 53 kDa, about 55 to 78 kDa and about 16 kDa are efficient antigens useful in the detection of all Pectinatus strains. This is particularly surprising as the 48-53 kDa protein has not been found to be antigenic as a native protein, and the 55-78 kDa protein acts as an antigen only with P . frisingiensis . Instead, the N-terminal fragments act as antigens common to both Pectinatus species.
- N-terminal fragment of the 48-53 kDa protein was very similar to the N-terminal sequence of a 40-50 kDa protein of another beer spoilage bacterium i.e. Megasphaera resulting in cross-reactive antibodies.
- the determined N-terminal sequence of the 48-53 kDa protein is Sequence No. 1
- the N-terminal sequence of the 55-78 kDa protein is Sequence No. 2
- the N-terminal sequence of the 16 kDa protein is Sequence No. 6 in the sequence list.
- a characteristic feature of the peptide accord ⁇ ing to the invention is that its antigenic determinant is Ala Ala Asn Pro Phe Ser Asp Val Pro Ala Asp Ser Ser Ala Tyr Asp Ala Val Ser Lys Leu Ala Ala Asp Asp Ser Val (Seq. No. 1), or a subsequence or derivative thereof; or Ala Leu Val Val Lys Asn Asn Met Ser Ala Leu Asn Thr Leu Asn lie Met Ser Lys Asn Asn Lys Asn Leu Ala (Seq. No 2), or a subsequence or derivative thereof; or Met lie Lys Pro Leu Gly Asp Gin Xaa Val lie Gin Asp Ser Glu (Seq. No 6) or a subsequence or derivative thereof.
- the three-letter abbreviations of the amino acids used herein read as follows:
- Ala alanine
- Asn asparagine
- Xaa valine or isoleucine
- the invention also relates to peptides having an antigenically active subsequence of the above sequences as an anti ⁇ genic determinant.
- Subsequences comprising approxim ⁇ ately the first 15 N-terminal amino acids are useful. It is obvious that the deletion, addition or substitution of a few amino acids in the above amino acid sequences or their subsequences by an amino acid of the same type or a chemical derivative does not necessarily affect the antigenic properties of the peptides, and therefore the invention further relates to peptides having the antigenically active derivat- ives of the above sequences or their subsequences as antigenic determinants.
- antigenically active refers to a compound which is able to elicit anti ⁇ bodies.
- An antigenic determinant is a molecule portion reacting with the antibody.
- the above-mentioned peptides can be used as antigens, thus obtaining antibodies useful in the immunological detection of Pectinatus bacteria.
- the sample to be analyzed is thus reacted with the antibody and the amount of reactive antibodies is measured, either directly or by means of an anti- antibody or an antibody binding molecule in a conventional way.
- the binding of the antibodies indicates the presence of the bacteria.
- the invention thus also relates to the use of the peptides as antigens, to antibodies raised against the peptides, and to a method for detecting Pectinatus bacteria by reacting a sample suspected to contain Pectinatus with the antibodies.
- Seq. No. 1 and subsequences and derivatives thereof it is further possible to detect Megasphaera bacteria.
- the desired antibodies can be produced by conjugating the peptide according to the invention with a carrier molecule and then utilizing the obtained conjugate in immunization to produce the antibody.
- the peptide Ala Leu Val Val Lys Asn Asn Met Ser Ala Leu Asn Thr Leu Asn (Seq. No. 4) or a subsequence of derivative thereof can also be used as an immunogenic carrier molecule as such.
- the invention will be described in greater detail below.
- Pectinatus strains were grown anaerobically, the cells were harvested, washed and extracted by HC1 to remove the surface layer. The cell debris was separ- ated and SDS-PAGE was performed on the extracts, as described by Hakalehto E. and Finne J., 1990, FEMS Microbiology Letters . 67, 307-312. Proteins of 48 to 53 kDa (about 51 kDa on the average), 55 to 78 kDa (about 63 kDa on the average) and 16 kDa were identified and their N-terminal sequences were determined by an automatic sequencer. All strains studied had identical sequences except for site 9 in the 16 kDa protein.
- the peptides according to the N-terminal sequence were then synthesized by the solid phase method. It is, of course, also possible to synthesize the peptides by other conventional methods, such as the liquid phase synthesis or the recombinant DNA technique.
- the peptides were used for the production of antisera by injecting them into a rabbit as such or conjugated with keyhole limpet hemocyanin. After immunization the sera were recovered.
- the reactivity of the obtained antibodies was studied with different Pectinatus strains by the immunoblotting method (Hakalehto E. and Finne J. , 1990, FEMS Microbiology Letters 67, 307-312). It was found that the N-terminal fragments of the 48-53 kDa protein, the 55-78 kDa protein and the 16 kDa protein act as efficient antigens and that these antigens were present in both the P . frisingiensis and P. cerevisiiphilus strains.
- the P. frisingiensis strains ATCC 33332, VT -E- 81141, VTT-E-80121, VTT-E-83170, VTT-E-87205, VTT-E- 88310 and VTT-E-87295, and the P. cerevisiiphilus strains DSM 20466 and ATCC 29359 were grown in a PYG broth (1% of peptone, 1% of yeast extract and 2% of glucose) in anaerobic Gas Pak jars at 30°C for 3 to 4 days. Oxygen was removed from the broth by boiling prior to incubation.
- the gels were blotted on PVDF membranes (Immobilon P®, Millipore) stained by Coomassie Brilliant Blue, and the 48-53 kDa, 55-78 kDa and 16 kDa proteins were cut off and dissolved in acetonitrile for sequencing.
- N-terminal sequences of the proteins isol ⁇ ated in Example 1 were determined by Edman degradation using a peptide sequencer of Applied Biosystems.
- the first 27 N-terminal amino acids of the 48-53 kDa protein of the ATCC 33332 strain were determined. They were as follows: Ala Ala Asn Pro Phe Ser Asp Val Pro Ala Asp Ser Ser Ala Tyr Asp Ala Val Ser Lys Leu Ala Ala Asp Asp Ser Val (Seq. No. 1).
- the first 20 N- terminal amino acids of the VTT-E-80121, DSM 20466, VTT-E-87295 and VTT-E-88310 strains were identical with the first 20 amino acids of the ATCC 33332 strain, and the first 10 N-terminal amino acids of the VTT-E-83170 strain were also identical with those of the above strains.
- the first 25 N-terminal amino acids of the 55-78 kDa protein of the ATCC 33332 strain were determined. They were as follows: Ala Leu Val Val Lys Asn Asn Met Ser Ala Leu Asn Thr Leu Asn lie Met Ser Lys Asn Asn Lys Asn Leu Ala (Seq. No. 2).
- the first 20 amino acids of the DSM 20466 and VTT-E-81141 strains, the first 15 amino acids of the VTT-E-80121 and VTT-E-83170 strains, the first 11 amino acids of the VTT-E-88310 strain, and the first 10 amino acids of the VTT-E- 87295 and ATCC 29359 strains were identical with the respective amino acids of the ATCC 33332 strain.
- the first 15 N-terminal amino acids of the 16 kDa protein of the P. cerevisiiphilus strains ATCC 29359 and DSM 20466 were Met lie Lys Pro Leu Gly Asp Gin Val Val lie Gin Asp Ser Glu (Seq. No. 7), and the ten first N-terminal amino acids of the same protein of the P. frisingiensis strains VTT-E-80121, VTT-E- 83170, VTT-E-87205 and VTT-E-88310 were identical except for site 9, where there was a species dependent difference, i.e. the amino acid was lie instead of Val.
- a peptide synthesizer utilizing the solid phase method (Applied Biosystems 431A Automated Peptide Synthesizer) and the Fmoc strategy were used to synthesize the protein fragments containing the first 15 N-terminal amino acids in the 48-53 kDa protein, the 55-78 kDa protein, and the 16 kDa protein, i.e. the following peptides: Ala Ala Asn Pro Phe Ser Asp Val Pro Ala Asp Ser Ser Ala Tyr (Seq. No. 3), Ala Leu Val Val Lys Asn Asn Met Ser Ala Leu Asn Thr Leu Asn (Seq. No. 4), and Met lie Lys Pro Leu Gly Asp Gin Val Val lie Gin Asp Ser Glu (Seq. No. 7) referred to below as peptide A, peptide B and peptide C.
- the peptides (A, B and C) synthesized in Example 3 and conjugated with keyhole limpet hemocyanin were injected into rabbits under the skin and into the muscle as described earlier (Liu, F. T. et al. , 1979, Biochemistry 3J3, 690-697).
- a cysteine had been attached to the C-terminal end of the peptides by the solid-phase peptide synthesizer.
- Peptide B was also injected as such, without conjugation.
- the rabbits were immunized with about 0.5 to 1 mg of peptide/rabbit, 4 to 5 times at intervals of two weeks. The sera were recovered after 1 to 4 months from the first injection.
- peptide B pre- cipitated quite rapidly in Ca 2+ - and Mg + -free phosphate buffered saline solution (CMF-PBS). This precipitate was extremely insoluble. When observed in electron micrographs, the precipitates were found to be fibrilles, which resembled the outlook of fibrilles formed by fragments of the ⁇ A4-amyloid peptide detected in the brains of patients suffering from Altzheimer's disease (Fraser, P. et al . , 1992, J. Neurochem. , 5_9_, 1531-1540).
- peptide B was also used as an immunogen as such without any carrier and it was found to elicit the same types of antibodies as peptide B coupled to keyhole limpet hemocyanin. Obviously peptide B could act as a carrier for other antigens.
- Example 4 The antibodies obtained in Example 4 were used in immunoblotting in accordance with the Western blotting method.
- SDS-PAGE was performed on the hydro- chloric acid extracts of the strains shown in Table 1, as set forth in Example 1.
- the gel was transferred to the Trans-Blot® Cell apparatus of Bio-Rad, where the proteins contained in the gel were transferred by an electric current (90 mA) in a buffer solution to an Immobilon®-P membrane (Millipore). After a run of about 60 minutes the membranes were transferred into calcium- and magnesium-free phosphate buffered saline (CMF-PBS), pH 7.4, containing 0.5% Tween 20 and 1% milk powder for pre-incubation.
- CMF-PBS calcium- and magnesium-free phosphate buffered saline
- the membranes were washed in CMF-PBS containing 0.05% Tween 20 and 1% milk powder, and then incubated for 80 min together with antibodies which were obtained in Example 4 and diluted with the last-mentioned CMF-PBS, and then the membranes were rewashed, as above.
- the membranes were transferred into a secondary antibody solution (P 217, Dako-immunoglobulins) for 60 minutes, and the washes were repeated. Staining was performed with diamino- benzidine (15 mg/30 ml) in the presence of hydrogen peroxide (15 ⁇ l of 30% hydrogen peroxide/30 ml) in the dark.
- the results for peptides A and B are shown in Table 1.
- the table also shows the antibody reactions of native proteins with respect to antibodies elicited by whole cells. These antibodies were prepared as described above (Hakalehto E. and Finne J., 1990, FEMS Microbiology Letters 62, 307- 312).
- Seq. No. 5 This sequence is a subsequence of Seq. No. 1 differ- ing from it only at four sites.
- a peptide having Seq. No. 5 was synthesized as described in Example 3, and cystein was attached to the C-terminal end of the peptide before coupling it to the keyhole limpet hemocyanin.
- Antibodies to said peptide were prepared as described in Example 4 and immunoblotted as in Example 5 using a serum dilution of 1:100-1:1000.
- the antibodies reacted strongly and specifically not only with the protein of 40-50 kDa of the Megasphaera strain ATCC 43254, from which the sequence was derived, but also with the 48-53 kDa protein of the Pectinatus strains ATCC 33332 and DSM 20466.
- MOLECULE TYPE protein
- FRAGMENT TYPE N-terminal
- MOLECULE TYPE protein
- FRAGMENT TYPE N-terminal
- MOLECULE TYPE protein
- FRAGMENT TYPE N-terminal
- MOLECULE TYPE protein
- FRAGMENT TYPE N-terminal
- ORGANISM Pectinatus cerevisiiphilus
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU51785/93A AU5178593A (en) | 1992-10-23 | 1993-10-21 | Protein fragments of the (pectinatus) bacterium |
EP93922966A EP0666870A1 (en) | 1992-10-23 | 1993-10-21 | PROTEIN FRAGMENTS OF THE $i(PECTINATUS) BACTERIUM |
JP6510741A JPH08502506A (en) | 1992-10-23 | 1993-10-21 | Protein fragment of Pectinatus bacteria |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI924835A FI94051C (en) | 1992-10-23 | 1992-10-23 | Pectinatus bacterial protein fragments |
FI924835 | 1992-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994010204A1 true WO1994010204A1 (en) | 1994-05-11 |
Family
ID=8536105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FI1993/000431 WO1994010204A1 (en) | 1992-10-23 | 1993-10-21 | Protein fragments of the pectinatus bacterium |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0666870A1 (en) |
JP (1) | JPH08502506A (en) |
AU (1) | AU5178593A (en) |
FI (1) | FI94051C (en) |
WO (1) | WO1994010204A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997020071A1 (en) * | 1995-11-28 | 1997-06-05 | Asahi Breweries, Ltd. | Detection of bacterium belonging to the genus pectinatus |
-
1992
- 1992-10-23 FI FI924835A patent/FI94051C/en active IP Right Grant
-
1993
- 1993-10-21 AU AU51785/93A patent/AU5178593A/en not_active Abandoned
- 1993-10-21 WO PCT/FI1993/000431 patent/WO1994010204A1/en not_active Application Discontinuation
- 1993-10-21 JP JP6510741A patent/JPH08502506A/en active Pending
- 1993-10-21 EP EP93922966A patent/EP0666870A1/en not_active Withdrawn
Non-Patent Citations (3)
Title |
---|
Dialog Information Services, File 5, BIOSIS, Dialog Accession No. 10000338, BIOSIS Number: 95000338, KLUGBAUER N. et al.: "Subunit Beta of Adenosine Triphosphate Synthase of Pectinatus-Frisingensis and Lactobacillus-Casei", Syst Appl Microbiol 15 (3), 1992, 323-330. * |
FEMS Microbiology Letters, Volume 67, 1990, ELIAS HAKALEHTO et al., "Identification by Immunoblot Analysis of Major Antigenic Determinants of the Anaerobic Beer Spoilage Bacterium Genus Pectinatus", page 307 - page 312. * |
International Journal of Systematic Bacteriology, Volume 33, No. 3, July 1983, C.-H. LAI et al., "Centipeda Periodontii Gen. Nov., Sp. Nov. from Human Periodontal Lesions", page 628 - page 635. * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997020071A1 (en) * | 1995-11-28 | 1997-06-05 | Asahi Breweries, Ltd. | Detection of bacterium belonging to the genus pectinatus |
EP0806483A1 (en) * | 1995-11-28 | 1997-11-12 | Asahi Breweries, Ltd. | Detection of bacterium belonging to the genus pectinatus |
EP0806483A4 (en) * | 1995-11-28 | 2000-06-07 | Asahi Breweries Ltd | Detection of bacterium belonging to the genus pectinatus |
Also Published As
Publication number | Publication date |
---|---|
FI94051B (en) | 1995-03-31 |
FI94051C (en) | 1995-07-10 |
FI924835A0 (en) | 1992-10-23 |
EP0666870A1 (en) | 1995-08-16 |
JPH08502506A (en) | 1996-03-19 |
AU5178593A (en) | 1994-05-24 |
FI924835A (en) | 1994-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0474313B1 (en) | Nucleotide sequence coding for an outer membrane protein from Neisseria meningitidis and use of said protein in vaccine preparations | |
Nachamkin et al. | Campylobacter jejuni | |
Pancholi et al. | Isolation and characterization of the cell-associated region of group A streptococcal M6 protein | |
EP0378881B1 (en) | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines | |
NO179164B (en) | Process for preparing an immunogen conjugate | |
CA2549188A1 (en) | Use of proteins and peptides coded by the genome of a novel strain of sars-associated coronavirus | |
Ambler | The amino acid sequence of cytochrome c′ from Alcaligenes sp. NCIB 11015 | |
EP0500736B1 (en) | Recombinant vaccine for porcine pleuropneumonia | |
Singh et al. | Antigenic determinants of the OmpC porin from Salmonella typhimurium | |
Ullmann et al. | Immunochemistry of the cell walls of Listeria monocytogenes | |
Kraus et al. | Vimentin-cross-reactive epitope of type 12 streptococcal M protein | |
EP2262828B1 (en) | Compositions, methods and kits | |
JPH07502896A (en) | Multifunctional surface proteins of streptococci | |
Wietzerbin et al. | Structural study of the poly-l-Glutamic acid of the cell wall of Mycobacterium tuberculosis var hominis, strain Brevannes | |
Pugsley et al. | Comparison of colicins B-K260 and D-CA23: purification and characterization of the colicins and examination of colicin immunity in the producing strains | |
WO1994010204A1 (en) | Protein fragments of the pectinatus bacterium | |
WO2000039310A9 (en) | Rubredoxin fusion proteins, protein expression system and methods | |
EP1414860A2 (en) | Pan-specific monoclonal antibody | |
Finlay et al. | Major antigenic determinants of F and ColB2 pili | |
Olson et al. | Identification of functional epitopes of Pseudomonas aeruginosa exotoxin A using synthetic peptides and subclone products | |
Baleux et al. | Novel version of multiple antigenic peptide allowing incorporation on a cysteine functionalized lysine tree | |
Seidl et al. | The Immunochemistry of Peptidoglycan: Antibodies against a Synthetic Immunogen Cross‐Reacting with an Interpeptide Bridge of Peptidoglycan | |
US5840513A (en) | Antibodies directed to pagC peptides for the detection of salmonellae | |
WO1988006594A1 (en) | Synthetic anti-caries vaccine | |
US5919640A (en) | Streptococcus suis adhesin protein and method for producing it |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1995 416818 Date of ref document: 19950414 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993922966 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1993922966 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993922966 Country of ref document: EP |